Molecule
Pilocarpine is a cholinergic receptor agonist. It is available as tablets, eye drops and ophthalmic solution for oral use. MedsAcross supplies Pilocarpine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
SALAGEN ® Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck, and 2) the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome.
Source: US FDA prescribing information
Regardless of the indication, the starting dose in patients with moderate hepatic impairment should be 5 mg twice daily, followed by adjustment based on therapeutic response and tolerability. Patients with mild hepatic insufficiency do not require dosage reductions. The use of pilocarpine in patients with severe hepatic insufficiency is not recommended. If needed, refer to the Hepatic Insufficiency subsection of the Precautions section of this label for definitions of mild, moderate and severe hepatic impairment. Head & Neck Cancer Patients: The recommended initial dose of SALAGEN ® Tablets is 5 mg taken three times a day. Dosage should be titrated according to therapeutic response and tolerance. The usual dosage range is up to 15-30 mg per day.
Source: US FDA prescribing information
SALAGEN ® Tablets are contraindicated in patients with uncontrolled asthma, known hypersensitivity to pilocarpine, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle closure) glaucoma.
Source: US FDA prescribing information
Cardiovascular Disease: Patients with significant cardiovascular disease may be unable to compensate for transient changes in hemodynamics or rhythm induced by pilocarpine. Pulmonary edema has been reported as a complication of pilocarpine toxicity from high ocular doses given for acute angle-closure glaucoma. Pilocarpine should be administered with caution in and under close medical supervision of patients with significant cardiovascular disease. Ocular: Ocular formulations of pilocarpine have been reported to cause visual blurring which may result in decreased visual acuity, especially at night and in patients with central lens changes, and to cause impairment of depth perception. Caution should be advised while driving at night or performing hazardous activities in reduced lighting.
Source: US FDA prescribing information
Head & Neck Cancer Patients: In controlled studies, 217 patients received pilocarpine, of whom 68% were men and 32% were women. Race distribution was 91% Caucasian, 8% Black, and 1% of other origin. Mean age was approximately 58 years. The majority of patients were between 50 and 64 years (51%), 33% were 65 years and older and 16% were younger than 50 years of age. The most frequent adverse experiences associated with SALAGEN ® Tablets were a consequence of the expected pharmacologic effects of pilocarpine. Adverse Event Pilocarpine HCl Placebo 10 mg t.i.d. (30 mg/day) 5 mg t.i.d.
Source: US FDA prescribing information
Pilocarpine should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances. Drugs with parasympathomimetic effects administered concurrently with pilocarpine would be expected to result in additive pharmacologic effects. Pilocarpine might antagonize the anticholinergic effects of drugs used concomitantly. These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium).
Source: US FDA prescribing information
Store up to 25°C (77°F), excursions permitted to 15°-30°C (59°-86°F). They are supplied as follows: NDC 59212-775-10 bottles of 100 Store up to 25°C (77°F), excursions permitted to 15°-30°C (59°-86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
9 presentations of Pilocarpine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Pilocarpine 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Pilocarpine 10 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Pilocarpine 20 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Pilocarpine 40 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Pilocarpine 7.5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Qlosi 4 mg/mL ophthalmic solutionOphthalmic Cold chain | Orasis Pharmaceuticals | US FDA | Available on request |
| Pilocarpine 12.5 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Salagen 5 mg tabletOral | Advanz Pharma | US FDA | Available on request |
| Salagen 7.5 mg tabletOral | Advanz Pharma | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 29 July 1974 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Pilocarpine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 9 presentations of Pilocarpine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Pilocarpine, including Qlosi, Salagen.
Yes. The US FDA first approved Pilocarpine on 29 July 1974, according to Drugs@FDA.
At least one listed presentation of Pilocarpine must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Pilocarpine is classified under ATC code N07AX01 (Pilocarpine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.